| scholarly article | Q13442814 |
| P2093 | author name string | J Park | |
| T Patel | |||
| G J Gores | |||
| L Tadlock | |||
| P2860 | cites work | Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways | Q24309037 |
| Gp130 and the interleukin-6 family of cytokines | Q28237653 | ||
| A synthetic inhibitor of the mitogen-activated protein kinase cascade | Q28367955 | ||
| PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo | Q28609356 | ||
| Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis | Q29547567 | ||
| SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1 | Q29620495 | ||
| Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes | Q35824326 | ||
| Interleukin-6: structure-function relationships. | Q36280356 | ||
| Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32. | Q37361913 | ||
| Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase | Q40964415 | ||
| Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma | Q41004779 | ||
| Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line | Q41085962 | ||
| Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. | Q41173912 | ||
| Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line | Q41445780 | ||
| Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines | Q41464352 | ||
| Interleukin 6 and its receptor: ten years later | Q41722189 | ||
| The pathobiology of biliary epithelia | Q71933958 | ||
| Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro | Q72094183 | ||
| Biliary interleukin-6 and tumor necrosis factor-alpha in patients undergoing endoscopic retrograde cholangiopancreatography | Q73454409 | ||
| Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase | Q73575389 | ||
| Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker | Q74397599 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| P304 | page(s) | 1128-1133 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line | |
| P478 | volume | 30 |
| Q45851469 | A New Preoperative Prognostic System Combining CRP and CA199 For Patients with Intrahepatic Cholangiocarcinoma. |
| Q38241837 | A clinical perspective on the role of chronic inflammation in gastrointestinal cancer |
| Q35620650 | A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. |
| Q37691482 | A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor |
| Q37045823 | AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma |
| Q37878880 | Aberrant DNA methylation profile in cholangiocarcinoma |
| Q28201030 | Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) β-hydroxylase suppress migration of cholangiocarcinoma cells |
| Q38720813 | Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma |
| Q34253944 | Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies |
| Q56379222 | Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review |
| Q33869507 | C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma |
| Q26865200 | Cancer review: Cholangiocarcinoma |
| Q39840008 | Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. |
| Q37505664 | Cell and molecular biology of the novel protein tyrosine-phosphatase-interacting protein 51. |
| Q36962011 | Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives |
| Q33965702 | Cholangiocarcinoma: Current concepts and insights |
| Q36900063 | Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment |
| Q34000079 | Cholangiocarcinoma: modern advances in understanding a deadly old disease |
| Q34959174 | Cholangiocarcinoma: molecular pathways and therapeutic opportunities |
| Q34194655 | Cholangiocarcinoma: new insights into disease pathogenesis and biology. |
| Q73315119 | Cholangiocarcinoma: preventing invasion as anti-cancer strategy |
| Q28073195 | Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers |
| Q38505216 | Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy |
| Q40675697 | Double-stranded RNA activates a p38 MAPK-dependent cell survival program in biliary epithelia. |
| Q40214323 | Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth |
| Q34200081 | Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma |
| Q91937591 | Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study |
| Q37521588 | Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells |
| Q34648030 | Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes |
| Q35222052 | Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma |
| Q37060540 | Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor |
| Q57494345 | Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis |
| Q38812588 | Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). |
| Q37215137 | Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations |
| Q34459845 | FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling |
| Q34658511 | Foxa1 and Foxa2 regulate bile duct development in mice |
| Q37731958 | Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma |
| Q94502750 | Hepatic Macrophages in Liver Injury |
| Q27490901 | Hepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant Hepatocytes |
| Q53856522 | High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. |
| Q39926096 | Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. |
| Q35528356 | IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism |
| Q34804514 | IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway |
| Q46752331 | IL-6/STAT3/TFF3 signaling regulates human biliary epithelial cell migration and wound healing in vitro |
| Q26778328 | Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases |
| Q91742830 | Intercellular Communication between Hepatic Cells in Liver Diseases |
| Q40345898 | Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells |
| Q40621382 | Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways |
| Q36042724 | Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer |
| Q34882042 | Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes |
| Q35841978 | Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism |
| Q36520248 | Interleukin‑6 induces epithelial‑mesenchymal transition in human intrahepatic biliary epithelial cells |
| Q27002547 | Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies |
| Q35677763 | Intraoperative radiation therapy in the multimodality approach to hepatobiliary tract cancer |
| Q35962753 | Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF |
| Q53242746 | Long-term effect of curcumin down-regulates expression of tumor necrosis factor-α and interleukin-6 via modulation of E26 transformation-specific protein and nuclear factor-κB transcription factors in livers of lymphoma bearing mice. |
| Q37154242 | Mechanisms linking obesity and cancer |
| Q37169351 | Mechanisms of biliary carcinogenesis and growth |
| Q39397552 | Mechanisms of cholangiocyte responses to injury |
| Q34704784 | Mechanisms of oxysterol-induced carcinogenesis. |
| Q29547523 | MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer |
| Q34097997 | MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes |
| Q38217475 | Molecular mechanism of cholangiocarcinoma carcinogenesis |
| Q37878879 | Molecular mechanisms of cholangiocarcinoma |
| Q28273377 | Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events |
| Q35023456 | Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers |
| Q37801938 | Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics |
| Q34391135 | New insights on cholangiocarcinoma. |
| Q40633762 | Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance |
| Q34881846 | Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes |
| Q34656747 | Pathogenesis, diagnosis, and management of cholangiocarcinoma |
| Q88766400 | Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer |
| Q33964582 | Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China |
| Q35088166 | Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma |
| Q51314955 | Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile. |
| Q36199767 | Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management |
| Q57205167 | Prognostic Assessment of Three Single-Nucleotide Polymorphisms (GNB3825C>T,BCL2-938C>A,MCL1-386C>G) in Extrahepatic Cholangiocarcinoma |
| Q40413628 | Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. |
| Q33829684 | Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis |
| Q38138097 | Progranulin: a novel regulator of gastrointestinal cancer progression |
| Q40160527 | Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells |
| Q92651093 | Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma |
| Q34010481 | Regulation and deregulation of cholangiocyte proliferation |
| Q36972551 | Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer |
| Q33814914 | Serum lipid levels and the risk of biliary tract cancers and biliary stones: A population-based study in China |
| Q36388792 | Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing |
| Q57115352 | Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer |
| Q37250126 | Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways |
| Q46328640 | The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. |
| Q36494373 | The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1. |
| Q28288613 | The role of the hepatitis viruses in cholangiocarcinoma |
| Q36407783 | The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells |
| Q51018355 | Tumor-related gene changes in immunosuppressive Syrian hamster cholangiocarcinoma. |
| Q34811043 | Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth |
| Q30238895 | Update on the Diagnosis and Treatment of Cholangiocarcinoma |
| Q38954890 | miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator |
Search more.